GRINCH: Groningen Initiative on Reference Intervals in Children

Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease

NCT02073526 ·Status: COMPLETED

Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up

NCT03487900 ·Status: UNKNOWN ·Phase: NA

Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

NCT02421705 ·Status: RECRUITING ·Phase: NA

PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease

NCT01759017 ·Status: TERMINATED

Brain-Gut Interactions in Crohn's Disease

NCT02108938 ·Status: COMPLETED

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281 ·Status: TERMINATED ·Phase: PHASE2

Study of Factors and Mechanisms Influencing the Effects of Treatments in Crohn's Disease

NCT04135027 ·Status: UNKNOWN

NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease

NCT00936585 ·Status: TERMINATED ·Phase: NA

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

NCT01453946 ·Status: COMPLETED ·Phase: PHASE3

Golimumab Dried Blood Spot Analysis

NCT02910375 ·Status: UNKNOWN ·Phase: PHASE4

To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)

NCT02326155 ·Status: TERMINATED

Biomarkers to Predict and Monitor Response to Infliximab

NCT04655729 ·Status: UNKNOWN

Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM

NCT01663142 ·Status: COMPLETED

Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy

NCT00851565 ·Status: UNKNOWN ·Phase: PHASE4

Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases

NCT02508012 ·Status: COMPLETED ·Phase: NA

Long-term Follow-up of Anal Fistulae in Crohn's Disease Treated With Anti-TNFalpha and Interest of New MRI Sequences

NCT02883296 ·Status: COMPLETED ·Phase: NA

Surgically Resected Crohn's Disease Patients: Prognostic Factors for Re-operation and New Score Building

NCT03150238 ·Status: UNKNOWN

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631 ·Status: COMPLETED ·Phase: PHASE2

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

NCT03090139 ·Status: COMPLETED

Correlation Between RISANKIZUMAB's Trough Levels, Clinical and Biological Remission in Moderate to Severe Crohn's Disease: a Retrospective Multicentric Study

NCT06589895 ·Status: COMPLETED

Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)

NCT01218360 ·Status: COMPLETED

Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess

NCT02856763 ·Status: COMPLETED

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

NCT04646187 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353 ·Status: RECRUITING ·Phase: PHASE3

COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)

NCT00132899 ·Status: COMPLETED ·Phase: PHASE3